AXA Investment Managers’s BioMarin Pharmaceuticals BMRN Stock Holding History

AXA Investment Managers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$19.7M	Buy	+362,949	New	+$20.8M	0.05%	287

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AXA Investment Managers's BMRN Position: Q3 2025 in Review

AXA Investment Managers opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2025: 362,949 shares worth $19.7M. The stake represents 0.05% of the portfolio and ranks #287 among its holdings.

576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

AXA Investment Managers held 362,949 shares of BioMarin Pharmaceuticals worth $19.7M as of Q3 2025.
BioMarin Pharmaceuticals was a new AXA Investment Managers position in Q3 2025.
BioMarin Pharmaceuticals made up 0.05% of AXA Investment Managers's portfolio in Q3 2025, its #287 holding.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.